Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies

Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocco, Joseph M., Rosen, Lindsey B., Hong, Gloria H., Treat, Jennifer, Kreuzburg, Samantha, Holland, Steven M., Zerbe, Christa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141761/
https://www.ncbi.nlm.nih.gov/pubmed/34041472
http://dx.doi.org/10.1016/j.jtauto.2021.100102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141761/
https://www.ncbi.nlm.nih.gov/pubmed/34041472
http://dx.doi.org/10.1016/j.jtauto.2021.100102

Ejemplares similares